Five Prime Therapeutics

$22.90
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$2.63 (-10.23%) Today
-$0.18 (-0.78%) As of 1:29 PM UTC after-hours

Why Robinhood?

You can buy or sell FPRX and other stocks, options, and ETFs commission-free!

About FPRX

Five Prime Therapeutics, Inc. Common Stock, also called Five Prime Therapeutics, is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. Its product candidates includes, Cabiralizumab(FPA008), Bemarituzumab(FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, CA. The listed name for FPRX is Five Prime Therapeutics, Inc. Common Stock.

CEO
Tom Civik
Employees
87
Headquarters
South San Francisco, California
Founded
2001
Market Cap
974.21M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.06M
High Today
$26.25
Low Today
$22.92
Open Price
$25.68
Volume
1.47M
52 Week High
$26.25
52 Week Low
$1.75

FPRX Earnings

-$1.03
-$0.69
-$0.34
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 4, After Hours

You May Also Like

DEED
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure